A. Collier

Sally S Bebawy, Richard D Moore, J. Goedert, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Incidence of Non-AIDS-Defining Cancer in Antiretroviral Treatment-Naïve Subjects after Antiretroviral Treatment Initiation: An ACTG Longitudinal Linked Randomized Trials Analysis

A. Collier, D. Jacobson, S. Koletar, 2011, Oncology.

The attitudes of patients with advanced AIDS toward use of the medical futility rationale in decisions to forego mechanical ventilation.

D. Patrick, A. Collier, J. Curtis, 2000, Archives of internal medicine.

Anthropometric Differences between HIV-Infected Individuals Prior to Antiretroviral Treatment and the General Population from 1998–2007: The AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT) Cohort and NHANES

A. Collier, T. Hulgan, S. Krishnan, 2013, PloS one.

Clinical variables identify seronegative HCV co-infection in HIV-infected individuals.

I. Grant, D. Clifford, R. Ellis, 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER

I. Grant, D. Clifford, M. Ritchie, 2012, Journal of NeuroVirology.

Measurement of Naive CD4 Cells Reliably Predicts Potential for Immune Reconstitution in HIV

G. Robbins, R. Bosch, T. Schacker, 2010, Journal of acquired immune deficiency syndromes.

Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.

P. Sax, E. Daar, A. Collier, 2014, The Journal of antimicrobial chemotherapy.

Two-way mobile phone intervention compared with standard-of-care adherence support after second-line antiretroviral therapy failure: a multinational, randomised controlled trial.

M. Hughes, R. Gross, J. Mellors, 2019, The Lancet. Digital health.

Changing use of intensive care for HIV-infected patients with Pneumocystis carinii pneumonia.

A. Collier, L. Hudson, D. Greenberg, 1994, American journal of respiratory and critical care medicine.

Cellular immunity and target cell susceptibility in persons with repeated HIV-1 exposure.

M. McElrath, A. Collier, F. Hladik, 1999, Immunology letters.

Central Nervous System Manifestations in Human Immunodeficiency Virus Infection Without AIDS

H. Handsfield, C. Marra, W. Longstreth, 1992, Journal of acquired immune deficiency syndromes.

Invasion of the central nervous system by Treponema pallidum: implications for diagnosis and treatment.

H. Handsfield, A. Collier, C. Critchlow, 1988, Annals of internal medicine.

Cerebrospinal fluid treponemal antibodies in untreated early syphilis.

C. Marra, A. Collier, C. Critchlow, 1995, Archives of neurology.

Lower Genitourinary Tract Sources of Seminal HIV

A. Collier, L. Corey, J. Krieger, 2006, Journal of acquired immune deficiency syndromes.

Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America.

Richard D Moore, J. Goedert, Jeffrey N. Martin, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Complex Drug Interactions of the HIV Protease Inhibitors 3: Effect of Simultaneous or Staggered Dosing of Digoxin and Ritonavir, Nelfinavir, Rifampin, or Bupropion

A. Collier, E. Kharasch, D. Whittington, 2012, Drug Metabolism and Disposition.

Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein

P. Greenberg, A. Collier, L. Corey, 1991, The Lancet.

Central venous catheter-related bacteremia due to Tsukamurella species in the immunocompromised host: a case series and review of the literature.

A. Collier, S. Tabet, T. T. Nguyen, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

D. Mankoff, A. Collier, M. Muzi, 2006 .

A prospective study of hearing changes after beginning zidovudine or didanosine in HIV-1 treatment-naïve people

C. Marra, A. Collier, T. Rees, 2006, BMC infectious diseases.

Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals.

A. Collier, D. Kitch, T. Brown, 2016, The Journal of infectious diseases.

Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients

D. Richman, D. Havlir, A. Collier, 2000, AIDS.

A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.

M. Wulfsohn, M. Hirsch, C. Parker, 1990, The New England journal of medicine.

Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.

M. McElrath, P. Greenberg, A. Collier, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation.

Jeannie S. Huang, R. Haubrich, A. Zolopa, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

CD28-negative CD4+ and CD8+ T cells in antiretroviral therapy-naive HIV-infected adults enrolled in adult clinical trials group studies.

R. Bosch, A. Collier, S. Deeks, 2012, The Journal of infectious diseases.

The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial.

J. Cherrington, A. Collier, S. Deeks, 1997, The Journal of infectious diseases.

Determinants of antimicrobial prophylaxis use and treatment for wasting among patients with advanced human immunodeficiency virus disease in the United States, 1995-1998.

S. Assmann, E. Murphy, A. Collier, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Screening for distal sensory peripheral neuropathy in HIV-infected persons in research and clinical settings

C. Marra, A. Collier, P. Boutin, 1998, Neurology.

Long-Acting Injectable Antiretroviral Treatment Acceptability and Preferences: A Qualitative Study Among US Providers, Adults Living with HIV, and Parents of Youth Living with HIV.

A. Collier, J. Simoni, J. Christodoulou, 2019, AIDS patient care and STDs.

Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination.

H. Handsfield, A. Collier, L. Corey, 1988, Annals of internal medicine.

Switching to a Protease Inhibitor-Containing, Nucleoside-Sparing Regimen (Lopinavir/Ritonavir Plus Efavirenz) Increases Limb Fat But Raises Serum Lipid Levels: Results of a Prospective Randomized Trial (AIDS Clinical Trial Group 5125s)

A. Collier, S. Evans, M. Fischl, 2007, Journal of acquired immune deficiency syndromes.

Cryptosporidiosis after marrow transplantation: person-to-person transmission and treatment with spiramycin.

R. Miller, A. Collier, J. Meyers, 1984, Annals of internal medicine.

Lower CSF Aβ is Associated with HAND in HIV-Infected Adults with a Family History of Dementia.

I. Grant, R. Heaton, D. Clifford, 2016, Current HIV research.

Prospective cerebral MR study of HIV seropositive and seronegative men: correlation of MR findings with neurologic, neuropsychologic, and cerebrospinal fluid analysis.

C. Marra, W. Longstreth, A. Collier, 1992, AJNR. American journal of neuroradiology.

Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333.

D V Glidden, D. Glidden, C. Boucher, 2000, The Journal of infectious diseases.

Risk factors for HIV-1 shedding in semen.

J. Zeh, A. Collier, L. Corey, 1999, American journal of epidemiology.

Relationship between Antibody to LAV/HTLV‐III and the Natural Course of Subclinical Cellular Immune Dysfunction in Homosexual Men

H. Handsfield, A. Collier, J. Meyers, 1987, Sexually transmitted diseases.

Screening and Enrollment by Sex in HIV Clinical Trials in the United States.

A. Collier, S. Koletar, L. Smeaton, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

I. Grant, D. Clifford, R. Ellis, 2008, Archives of neurology.

Etravirine in CSF is highly protein bound.

I. Grant, D. Clifford, R. Ellis, 2013, The Journal of antimicrobial chemotherapy.

Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.

P. Sax, D. Haas, E. Daar, 2013, The Journal of infectious diseases.

Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings

M. Wulfsohn, S. Hammer, R. Schooley, 2012, PLoS medicine.

Early intervention in HIV infection

A. Collier, 1994 .

Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection

A. Collier, L. Corey, T. Tartaglione, 1991, Antimicrobial Agents and Chemotherapy.

Enrolled in ACTG Studies

R. Bosch, A. Collier, E. Connick, 2012 .

The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.

L. Resnick, A. Collier, M. Fischl, 1994, Journal of acquired immune deficiency syndromes.

Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood.

A. Collier, J. Hughes, L. Corey, 1998, The Journal of infectious diseases.

Seminal shedding of human immunodeficiency virus type 1 and human cytomegalovirus: evidence for different immunologic controls.

A. Collier, L. Corey, J. Krieger, 1995, The Journal of infectious diseases.

Integration of computational and experimental approaches to elucidate mechanisms of first-pass lymphatic drug sequestration and long-acting pharmacokinetics of the injectable triple-HIV drug combination TLC-ART 101.

A. Collier, D. Shen, R. Ho, 2020, Journal of pharmaceutical sciences.

Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects.

M. Emerman, M. McElrath, A. Collier, 1999, The Journal of infectious diseases.

Neurologic relapse after benzathine penicillin therapy for secondary syphilis in a patient with HIV infection.

C. D. Berry, A. Collier, T. Hooton, 1987, The New England journal of medicine.

A Pilot Study of Raltegravir Plus Combination Antiretroviral Therapy in Early Human Immunodeficiency Virus Infection: Challenges and Lessons Learned

J. Mullins, T. Chun, J. Justement, 2016, BioResearch open access.

SEX DIFFERENCES IN OUTCOMES FOR INDIVIDUALS PRESENTING FOR THIRD-LINE ANTIRETROVIRAL THERAPY.

M. Hughes, R. Gross, A. Collier, 2020, Journal of acquired immune deficiency syndromes.

The systematic development of attributes and levels for a discrete choice experiment of HIV patient preferences for long-acting antiretroviral therapies in the United States

A. Collier, J. Simoni, V. Marconi, 2021, AIDS Research and Therapy.

Regulatory T Cells and the Risk of CMV End-Organ Disease in Patients With AIDS

A. Zolopa, R. Bosch, A. Collier, 2014, Journal of acquired immune deficiency syndromes.

REGULATORY T CELLS AND THE RISK OF CMV END-ORGAN DISEASE IN AIDS PATIENTS

A. Zolopa, R. Bosch, A. Collier, 2014 .

Phase I study of high-dose, intravenous rsCD4 in subjects with advanced HIV-1 infection.

T. Schacker, A. Collier, L. Corey, 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Effects of traumatic brain injury on cognitive functioning and cerebral metabolites in HIV-infected individuals

Michael J. Taylor, C. Fennema-Notestine, T. Jernigan, 2011, Journal of clinical and experimental neuropsychology.

HIV-associated distal neuropathic pain is associated with smaller total cerebral cortical gray matter

David J. Miller, Michael J. Taylor, Greg G. Brown, 2014, Journal of NeuroVirology.

The quality of patient-doctor communication about end-of-life care: a study of patients with advanced AIDS and their primary care clinicians.

D. Patrick, A. Collier, J. Curtis, 1999, AIDS.

Why don't patients and physicians talk about end-of-life care? Barriers to communication for patients with acquired immunodeficiency syndrome and their primary care clinicians.

D. Patrick, A. Collier, J. Curtis, 2000, Archives of internal medicine.

HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy

Michael J. Taylor, A. Gamst, C. Fennema-Notestine, 2010, Neurology.

A Conjoint Analysis of the Acceptability of Targeted Long-Acting Injectable Antiretroviral Therapy Among Persons Living with HIV in the U.S.

A. Collier, J. Simoni, J. Christodoulou, 2019, AIDS and Behavior.

Safety, Pharmacokinetics, and Antiviral Activity of AMD3100, a Selective CXCR4 Receptor Inhibitor, in HIV-1 Infection

Dominique Schols, M. Lederman, C. Flexner, 2004, Journal of acquired immune deficiency syndromes.

Antiretroviral hair levels, self-reported adherence, and virologic failure in second-line regimen patients in resource-limited settings

K. Ruxrungtham, R. Gross, S. Kerr, 2021, AIDS.

Low Cerebrospinal Fluid Concentrations of the Nucleotide HIV Reverse Transcriptase Inhibitor, Tenofovir

I. Grant, D. Clifford, R. Ellis, 2012, Journal of acquired immune deficiency syndromes.

Plasma viremia in human immunodeficiency virus infection.

A. Collier, L. Corey, M. Leuther, 1989, The New England journal of medicine.

Identification of multiple strains of cytomegalovirus in homosexual men.

H. Handsfield, A. Collier, L. Corey, 1989, The Journal of infectious diseases.

Cervical but not urinary excretion of cytomegalovirus is related to sexual activity and contraceptive practices in sexually active women.

H. Handsfield, A. Collier, L. Corey, 1995, The Journal of infectious diseases.

Use of and attitudes about alternative and complementary therapies among outpatients and physicians at a municipal hospital.

A. Collier, D. Buchwald, L. Robinson, 2000, Journal of alternative and complementary medicine.

Recovery of human immunodeficiency virus type 1 from semen: minimal impact of stage of infection and current antiviral chemotherapy.

V L Murphy, A. Collier, L. Corey, 1991, The Journal of infectious diseases.

Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects

I. Grant, R. Heaton, D. Clifford, 2019, AIDS.

Investigating the contribution of CYP2J2 to ritonavir metabolism in vitro and in vivo.

Jashvant D Unadkat, Evan D Kharasch, A. Collier, 2014, Biochemical pharmacology.

Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high‐fat meal

A. Collier, J. Unadkat, S. S. Crosby, 1990, AIDS.

Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy

T. Blaschke, L. Sheiner, K. Squires, 1997, Antimicrobial agents and chemotherapy.

A reduced dose of zidovudine in patients with AIDS.

A. Tsiatis, J. Golmard, A. Mallet, 1991, The New England journal of medicine.

A pilot study of low-dose zidovudine in human immunodeficiency virus infection.

D. Richman, C. Pettinelli, S. Spector, 1990, The New England journal of medicine.

Strategies for second-line antiretroviral therapy in adults with HIV infection.

A. Collier, M. Schwartz, Ann C. Collier, 1999, Advances in experimental medicine and biology.

Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy

L B Sheiner, T F Blaschke, D Verotta, 1997, Antimicrobial agents and chemotherapy.

Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients

A. Collier, J. Toole, H. Jaffe, 1995, Antimicrobial agents and chemotherapy.

Combination Therapy with Zidovudine and Didanosine Compared with Zidovudine Alone in HIV-1 Infection

P. Volberding, A. Collier, L. Corey, 1993, Annals of Internal Medicine.

Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression

M. Hirsch, D. Richman, D. Havlir, 2001, AIDS.

Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy.

S. Hammer, D. Katzenstein, M. Hughes, 1998, Journal of Infectious Diseases.

A randomized placebo-controlled trial of recombinant human interferon alpha 2a in patients with aids

R. Schooley, C. Crumpacker, H. Handsfield, 1988 .

“Lighten This Burden of Ours”: Acceptability and Preferences Regarding Injectable Antiretroviral Treatment Among Adults and Youth Living With HIV in Coastal Kenya

A. Collier, J. Simoni, S. Graham, 2021, Journal of the International Association of Providers of AIDS Care.

Combination and Monotherapy with Zidovudine and Zalcitabine in Patients with Advanced HIV Disease

Ann Collier, Judith Feinberg, A. Collier, 1995, Annals of Internal Medicine.

A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome

M. Wulfsohn, M. Hirsch, T. Merigan, 1990 .

Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.

C. Fichtenbaum, P. Sax, E. Daar, 2013, The Journal of infectious diseases.

Efficacy of combination antiretroviral therapy.

A. Collier, 1996, Advances in experimental medicine and biology.

Participants Switching to Second-Line Antiretroviral Therapy with Susceptible Virus Display Inferior Adherence and Worse Outcomes: An Observational Analysis.

R. Gross, A. Collier, C. Godfrey, 2021, AIDS patient care and STDs.

Prevalence and Impact of Minority Variant Drug Resistance Mutations in Primary HIV-1 Infection

Lisa M. Frenkel, A. Collier, L. Frenkel, 2011, PloS one.

Pretreatment Factors Associated With 3-Year (144-Week) Virologic and Immunologic Responses to Potent Antiretroviral Therapy

R. Bosch, A. Collier, C. Benson, 2007, Journal of acquired immune deficiency syndromes.

Brief Report: Significant Decreases in Both Total and Unbound Lopinavir and Amprenavir Exposures During Coadministration: ACTG Protocol A5143/A5147s Results.

A. Collier, J. Rigdon, F. Aweeka, 2015, Journal of acquired immune deficiency syndromes.

Significant Decreases in both Total and Unbound Lopinavir and Amprenavir Exposures during Co-administration: ACTG Protocol A5143/A5147s Results

A. Collier, J. Rigdon, F. Aweeka, 2015 .

Complex Drug Interactions of HIV Protease Inhibitors 2: In Vivo Induction and In Vitro to In Vivo Correlation of Induction of Cytochrome P450 1A2, 2B6, and 2C9 by Ritonavir or Nelfinavir

A. Collier, E. Kharasch, D. Whittington, 2011, Drug Metabolism and Disposition.

Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients

F. Vaida, R. Heaton, D. Clifford, 2015, Journal of NeuroVirology.

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.

R. Haubrich, I. Grant, D. Clifford, 2011, The Journal of antimicrobial chemotherapy.

AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT): Rationale, Design, and Baseline Characteristics

R. Bosch, A. Collier, S. Koletar, 2008, HIV clinical trials.

Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1

D. Katzenstein, P. Sax, E. Daar, 2011, Annals of Internal Medicine.

Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants

G. Wilding, P. Sax, E. Daar, 2017, Therapeutic drug monitoring.

Qualitative and quantitative PCR measures of cytomegalovirus in patients with advanced HIV infection who require transfusions.

L. Kalish, A. Collier, R. Pollard, 2001 .

Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection

M. Hughes, R. Shafer, G. Robbins, 2010, AIDS.

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.

Lynne Peeples, David Katzenstein, Victoria A Johnson, 2009, The New England journal of medicine.

Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team.

J. Ioannidis, M. Hirsch, D. Richman, 1998, The New England journal of medicine.

Prevalence and predictive value of intermittent viremia with combination hiv therapy.

M. Hirsch, D. Richman, H. Günthard, 2001, JAMA.

Unintegrated circular HIV-1 DNA in the peripheral mononuclear cells of HIV-1-infected subjects: association with high levels of plasma HIV-1 RNA, rapid decline in CD4 count, and clinical progression to AIDS.

J. Zeh, A. Collier, L. Corey, 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Human herpesvirus 6 DNA in blood cells of human immunodeficiency virus-infected men: correlation of high levels with high CD4 cell counts.

T. Schacker, A. Collier, L. Corey, 1994, The Journal of infectious diseases.

Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: the Viral Activation Transfusion Study: a randomized controlled trial.

M. Lederman, L. Kalish, S. Assmann, 2001, JAMA.

Plasma human immunodeficiency virus (HIV) type 1 RNA load in men and women with advanced HIV-1 disease.

L. Kalish, A. Collier, T. Flanigan, 2000, Journal of Infectious Diseases.

Effect of early versus deferred antiretroviral therapy for HIV on survival.

Michael J Silverberg, Bryan Lau, Michael S Saag, 2009, The New England journal of medicine.

Zidovudine Compared With Didanosine in Patients With Advanced HIV Type I Infection and Little or No Previous Experience With Zidovudine

K. K. Lai, D. Katzenstein, M. Hirsch, 1995 .

A randomized, double-blind, phase I/II trial of tumor necrosis factor and interferon-gamma for treatment of AIDS-related complex (Protocol 025 from the AIDS Clinical Trials Group).

A. Collier, L. Corey, R. Coombs, 1992, AIDS research and human retroviruses.

Cerebrospinal fluid cell-free mitochondrial DNA is associated with HIV replication, iron transport, and mild HIV-associated neurocognitive impairment

I. Grant, R. Heaton, J. Connor, 2017, Journal of Neuroinflammation.

Association between cytomegalovirus seroconversion and upper genital tract infection among women attending a sexually transmitted disease clinic: a prospective study.

A. Collier, L. Corey, T. Derouen, 1998, The Journal of infectious diseases.

Lack of Effect on Survival of High-Dose Acyclovir and Zidovudine Compared with Zidovudine Alone for Acquired Immunodeficiency Syndrome

A. Collier, L. Corey, D. Schoenfeld, 1998, Antiviral Therapy.

Evaluation of cerebrospinal fluid in Southeast Asian refugees with reactive serologic tests for syphilis.

A. Collier, S. Lukehart, P. Kith, 1996, The Western journal of medicine.

Lifetime suicidal ideation and attempt are common among HIV+ individuals.

F. Vaida, I. Grant, R. Heaton, 2012, Journal of affective disorders.

White matter damage, neuroinflammation, and neuronal integrity in HAND

C. Fennema-Notestine, I. Grant, R. Heaton, 2018, Journal of NeuroVirology.

Imaging of Cyclosporine Inhibition of P-Glycoprotein Activity Using 11C-Verapamil in the Brain: Studies of Healthy Humans

Mark Muzi, David A. Mankoff, Jashvant D. Unadkat, 2009, Journal of Nuclear Medicine.

Verapamil P-glycoprotein Transport across the Rat Blood-Brain Barrier: Cyclosporine, a Concentration Inhibition Analysis, and Comparison with Human Data

Mark Muzi, David A. Mankoff, Jashvant D. Unadkat, 2006, Journal of Pharmacology and Experimental Therapeutics.

Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study.

Michael J. Taylor, F. Vaida, C. Fennema-Notestine, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Neurocognitive Impact of Substance Use in HIV Infection

I. Grant, R. Heaton, D. Clifford, 2011, Journal of acquired immune deficiency syndromes.

Fitness-Balanced Escape Determines Resolution of Dynamic Founder Virus Escape Processes in HIV-1 Infection

Dylan H. Westfall, J. Mullins, N. Frahm, 2015, Journal of Virology.

Conserved HIV-1 epitopes continuously elicit subdominant cytotoxic T-lymphocyte responses.

J. Mullins, M. McElrath, A. Collier, 2009, The Journal of infectious diseases.

Demographic Processes Affect HIV-1 Evolution in Primary Infection before the Onset of Selective Processes

Joshua T. Herbeck, Wenjie Deng, Morgane Rolland, 2011, Journal of Virology.

Treatment of primary HIV

A. Collier, J. Stekler, 2002, Current infectious disease reports.

Do HIV type 1 RNA levels provide additional prognostic value to CD4(+) T lymphocyte counts in patients with advanced HIV type 1 infection?

D. Spiegelman, A. Collier, M. Fischl, 2001, AIDS research and human retroviruses.

Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine

J. Gallant, D. Mehrotra, D. Haas, 2000, AIDS.

The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. The Women Infant Transmission Study Clinics. Virology Quality Assurance Program.

S. Hammer, D. Katzenstein, A. Collier, 1999, AIDS.

Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline

Anthony Gamst, Justin C McArthur, Ian Abramson, 2014, Neurology.

Diagnosing Symptomatic HIV-Associated Neurocognitive Disorders: Self-Report Versus Performance-Based Assessment of Everyday Functioning

I. Grant, R. Heaton, D. Clifford, 2011, Journal of the International Neuropsychological Society.

Defining Neurocognitive Impairment in HIV: Deficit Scores Versus Clinical Ratings

I. Grant, R. Heaton, D. Clifford, 2012, The Clinical neuropsychologist.

Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat

D. Richman, R. Heaton, D. Clifford, 2012, Journal of NeuroVirology.

Protective HIV-specific CD8+ T cells evade Treg cell suppression

S. Elahi, M. McElrath, A. Collier, 2011, Nature Medicine.

Selection on the Human Immunodeficiency Virus Type 1 Proteome following Primary Infection

David C. Nickle, Lawrence Corey, Jianhong Cao, 2006, Journal of Virology.

Superior Control of HIV-1 Replication by CD8+ T Cells Targeting Conserved Epitopes: Implications for HIV Vaccine Design

J. Mullins, T. Hertz, A. Collier, 2013, PloS one.

Env length and N-linked glycosylation following transmission of human immunodeficiency virus Type 1 subtype B viruses.

J. Mullins, A. Collier, L. Corey, 2008, Virology.

Novel Criteria for Diagnosing Acute and Early HIV Infection in a Multi-National Study of Early Antiretroviral Therapy Initiation.

B. Chi, J. Ananworanich, K. Ruxrungtham, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

No Time to Delay! Fiebig Stages and Referral in Acute HIV infection: Seattle Primary Infection Program Experience.

J. Mullins, A. Collier, R. Coombs, 2018, AIDS research and human retroviruses.

How Often does Treatment of Primary HIV Lead to Post-Treatment Control?

J. Mullins, A. Collier, S. Holte, 2015, Antiviral therapy.

Tolerability and Efficacy of PI Versus NNRTI-Based Regimens in Subjects Receiving HAART During Acute or Early HIV Infection

B. Walker, J. Margolick, F. Vaida, 2009, Journal of acquired immune deficiency syndromes.

Screening for acute HIV infection: lessons learned.

D. Nickle, M. Golden, A. Collier, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Virus-Specific CD8+ T-Cell Responses Better Define HIV Disease Progression than HLA Genotype

J. Mullins, M. McElrath, A. Collier, 2010, Journal of Virology.

Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment

J. Mullins, A. Collier, R. Coombs, 2020, PLoS pathogens.

Higher HIV-1 genetic diversity is associated with AIDS and neuropsychological impairment.

Sergei L. Kosakovsky Pond, D. Richman, I. Grant, 2012, Virology.

Alterations in T cell phenotype and human immunodeficiency virus type 1-specific cytotoxicity after potent antiretroviral therapy.

M. Hirsch, J. Schmitz, M. Kuroda, 2001, The Journal of infectious diseases.

Primary HIV infection

A. Collier, J. Stekler, 2004, Current HIV/AIDS reports.

Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens.

M. Hirsch, D. Richman, C. Petropoulos, 2000, JAMA.

Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus.

Lawrence Corey, James I Mullins, Susan Moir, 2007, The Journal of infectious diseases.

Zidovudine treatment of the AIDS dementia complex: Results of a placebo‐controlled trial

M. Hirsch, D. Richman, C. Gatsonis, 1993, Annals of neurology.

CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy

Susan Morgello, David Clifford, Florin Vaida, 2011, AIDS.

Relationship Between CD4+ T-Cell Counts/HIV-1 RNA Plasma Viral Load and AIDS-Defining Events Among Persons Followed in the ACTG Longitudinal Linked Randomized Trials Study

R. Bosch, A. Collier, S. Koletar, 2010, Journal of acquired immune deficiency syndromes.

A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.

S. Hammer, M. Saag, A. Collier, 2003, The Journal of infectious diseases.

Quantitation of human immunodeficiency virus in the blood.

A. Collier, L. Corey, R. Coombs, 1990, The New England journal of medicine.

Cytomegalovirus infection in women attending a sexually transmitted disease clinic.

H. Handsfield, A. Collier, L. Corey, 1990, The Journal of infectious diseases.

Characterizing HIV Medication Adherence for Virologic Success Among Individuals Living With HIV/AIDS: Experience With the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Cohort

E. Spitznagel, D. Clifford, J. McCutchan, 2014, Journal of HIV/AIDS & social services.

Complex Drug Interactions of HIV Protease Inhibitors 2: In Vivo Induction and In Vitro to In Vivo Correlation of Induction of Cytochrome P450 1A2, 2B6, and 2C9 by Ritonavir or Nelfinavir

A. Collier, E. Kharasch, D. Whittington, 2011, Drug Metabolism And Disposition.

Partner-based adherence intervention for second-line antiretroviral therapy (ACTG A5234): a multinational randomised trial.

G. Robbins, R. Gross, A. Collier, 2015, The lancet. HIV.

Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection.

M. Altfeld, J. Margolick, R. Schooley, 2011, The Journal of infectious diseases.

Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study.

F. Vaida, I. Grant, B. Ances, 2010, Archives of neurology.

Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial

R. Schooley, R. Gross, J. Mellors, 2022, Journal of the International AIDS Society.

Predictors of virologic outcome among people living with HIV who continue a protease inhibitor-based antiretroviral regimen following virologic failure with no or limited resistance

R. Gross, J. Mellors, A. Collier, 2023, AIDS Research and Therapy.

Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.

J. Mellors, A. Collier, B. Taiwo, 2016, The lancet. HIV.

Immunodeficiency at the Start of Combination Antiretroviral Therapy in Low-, Middle-, and High-Income Countries

B. Chi, J. Sterne, K. Anastos, 2013, Journal of acquired immune deficiency syndromes.

Late presentation for human immunodeficiency virus care in the United States and Canada.

Richard D Moore, J. Goedert, Jeffrey N. Martin, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Seroepidemiologic screening for antibodies to LAV/HTLV-III in Sri Lanka, 1980-1982.

H. Handsfield, R. Miller, A. Collier, 1985, The New England journal of medicine.

Quality of life among HIV-infected individuals failing first-line antiretroviral therapy in resource-limited settings

M. Hughes, A. Collier, Linda J Harrison, 2018, AIDS care.

HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.

D. Katzenstein, P. Sax, R. Bosch, 2012, The Journal of infectious diseases.

Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial

Kenneth A. Freedberg, Rochelle P. Walensky, Milton C. Weinstein, 2012, AIDS.

American Journal of Epidemiology Practice of Epidemiology Missing Data on the Estimation of the Prevalence of Accumulated Human Immunodeficiency Virus Drug Resistance in Patients Treated with Antiretroviral Drugs in North America

Richard D Moore, J. Goedert, B. Lau, 2022 .

Ethnic/Racial Disparities in Longitudinal Neurocognitive Decline in People With HIV

R. Heaton, D. Clifford, R. Ellis, 2022, Journal of acquired immune deficiency syndromes.

Increased mucosal neutrophil survival is associated with altered microbiota in HIV infection

T. Hope, A. Collier, M. Gale, 2019, PLoS pathogens.

Identifying the early post-HIV antibody seroconversion period.

J. Margolick, S. Little, R. Wellman, 2011, The Journal of infectious diseases.

Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation

J. Mellors, R. Bosch, C. Rinaldo, 2017, PLoS pathogens.

Weight gain following antiretroviral therapy (ART) initiation in ART-naïve people living with HIV in the current treatment era.

Brian R Wood, S. Lindström, M. Saag, 2020, Journal of acquired immune deficiency syndromes.

Differences in Neurocognitive Impairment Among HIV-Infected Latinos in the United States

I. Grant, R. Heaton, D. Clifford, 2017, Journal of the International Neuropsychological Society.

Genome‐wide association study of HIV‐associated neurocognitive disorder (HAND): A CHARTER group study

Zhongming Zhao, N. Schork, P. Jia, 2017, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy.

J. Siliciano, J. Mellors, R. Bosch, 2020, The Journal of infectious diseases.

Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication

R. Kaul, M. Ostrowski, C. Kovacs, 2010, AIDS.

Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy

F. Vaida, C. Fennema-Notestine, R. Heaton, 2017, The Journal of infectious diseases.

The prevalence and incidence of neurocognitive impairment in the HAART era

Justin C McArthur, Thomas D Parsons, Ronald J Bosch, 2007, AIDS.

Clinical validation of the NeuroScreen

C. Yiannoutsos, D. Clifford, L. Moo, 2005, Journal of NeuroVirology.

Concurrent Classification Accuracy of the HIV Dementia Scale for HIV-Associated Neurocognitive Disorders in the CHARTER Cohort

I. Grant, R. Heaton, D. Clifford, 2013, Journal of acquired immune deficiency syndromes.

Cytomegalovirus infection in homosexual men. Relationship to sexual practices, antibody to human immunodeficiency virus, and cell-mediated immunity.

H. Handsfield, A. Collier, L. Corey, 1987, The American journal of medicine.

Family history of dementia predicts worse neuropsychological functioning among HIV-infected persons.

Suzanne A. Moseley, F. Vaida, I. Grant, 2011, The Journal of neuropsychiatry and clinical neurosciences.

Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214.

B. Walker, R. Schooley, M. Hirsch, 2000, Journal of Infectious Diseases.

Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS.

S. Self, T. Chun, A. Fauci, 2001, The Journal of infectious diseases.

Higher levels of plasma inflammation biomarkers are associated with depressed mood and quality of life in aging, virally suppressed men, but not women, with HIV

R. Heaton, D. Clifford, R. Ellis, 2020, Brain, behavior, & immunity - health.

Combination therapy with zidovudine, didanosine and saquinavir.

A. Collier, L. Corey, D. Schoenfeld, 1996, Antiviral research.

Abnormal antibody responses in patients with persistent generalized lymphadenopathy

H. Handsfield, H. Ochs, A. Collier, 2004, Journal of Clinical Immunology.

Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration.

I. Grant, D. Clifford, R. Ellis, 2013, The Journal of antimicrobial chemotherapy.

Paresthesia Predicts Increased Risk of Distal Neuropathic Pain in Older People with HIV-Associated Sensory Polyneuropathy.

A. Simmons, F. Vaida, I. Grant, 2021, Pain medicine.

Central venous catheter-related bacteremia due to Tsukamurella species in the immunocompromised host

A. Collier, S. Tabet, T. T. Nguyen, 2002 .

Treatment with Commonly Used Antiretroviral Drugs Induces a Type I/III Interferon Signature in the Gut in the Absence of HIV Infection

T. Holtz, J. Baeten, M. McElrath, 2019, Cell reports. Medicine.

Poor quality of life and incomplete self-reported adherence predict second-line ART virological failure in resource-limited settings

M. Hughes, A. Collier, Linda J Harrison, 2021, AIDS care.

Comparative study of ceftriaxone and spectinomycin in the treatment of uncomplicated gonorrhea in women.

H. Handsfield, A. Collier, F. Judson, 1984, The American journal of medicine.

A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.

Lei Wang, Susan Little, Ann Collier, 2006, The Journal of infectious diseases.

Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy

C. Marra, A. Collier, K. Robertson, 2007, BMC infectious diseases.

Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study.

F. Vaida, I. Grant, D. Clifford, 2019, The lancet. HIV.

Neurocognitive impairment in HIV-infected individuals with previous syphilis

I. Grant, R. Heaton, D. Clifford, 2013, International journal of STD & AIDS.

Incidence Rate of and Factors Associated with Loss to Follow-up in a Longitudinal Cohort of Antiretroviral-Treated HIV-Infected Persons: An AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) Analysis

R. Bosch, A. Collier, S. Koletar, 2011, HIV clinical trials.

Factors Associated With CD8+ T-Cell Activation in HIV-1–Infected Patients on Long-term Antiretroviral Therapy

C. Flexner, R. Bosch, A. Collier, 2014, Journal of acquired immune deficiency syndromes.

Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER

I. Grant, D. Clifford, M. Ritchie, 2012, Journal of NeuroVirology.

Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen

R. Ellis, R. Bosch, A. Collier, 2017, AIDS.

Cognitive risk factors and neuropsychological performance in HIV infection.

C. Marra, W. Longstreth, A. Collier, 1993, The International journal of neuroscience.

Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication

M. Hirsch, D. Richman, D. Havlir, 2000, AIDS.

CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?

Richard D Moore, J. Goedert, Jeffrey N. Martin, 2010, AIDS research and therapy.

Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders

F. Vaida, C. Fennema-Notestine, A. Gamst, 2013, Journal of NeuroVirology.

Neurosyphilis and HIV infection

C. D. Berry, C. Beck-Sague, K. Jordan, 1987 .

The Role of Cohort Studies in Drug Development: Clinical Evidence of Antiviral Activity of Serotonin Reuptake Inhibitors and HMG-CoA Reductase Inhibitors in the Central Nervous System

I. Grant, R. Heaton, D. Clifford, 2007, Journal of Neuroimmune Pharmacology.

Neurocognitive SuperAging in Older Adults Living With HIV: Demographic, Neuromedical and Everyday Functioning Correlates

Jessica L. Montoya, D. Jeste, I. Grant, 2019, Journal of the International Neuropsychological Society.

Factors associated with remaining on initial randomized efavirenz-containing regimens

V. Johnson, J. Lok, R. Bosch, 2013, AIDS.

A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group.

J. Phair, M. Hirsch, S. Lagakos, 1995, The New England journal of medicine.

Prevalence of antibody to LAV/HTLV-III among homosexual men in Seattle.

H. Handsfield, A. Collier, R. Barnes, 1986, American journal of public health.

Primary HIV Infection Education: Knowledge and Attitudes of HIV-Negative Men Who Have Sex With Men Attending a Public Health Sexually Transmitted Disease Clinic

K. Holmes, M. Golden, A. Collier, 2006, Journal of acquired immune deficiency syndromes.

Relationships Among Neurocognitive Status, Medication Adherence Measured by Pharmacy Refill Records, and Virologic Suppression in HIV-Infected Persons

I. Grant, J. McCutchan, J. Atkinson, 2013, Journal of acquired immune deficiency syndromes.

Are there benefits to starting antiretroviral therapy during primary HIV infection? Conclusions from the Seattle Primary Infection Cohort vary by control group

R. Wellman, A. Collier, L. Corey, 2012, International journal of STD & AIDS.

Effect of co‐administration of efavirenz and nelfinavir on the pharmacokinetics of indinavir

A. Collier, J. Feinberg, R. Dicenzo, 2005 .

Lack of Resistance to Integrase Inhibitors among Antiretroviral-Naive Subjects with Primary HIV-1 Infection, 2007–2013

J. Mullins, S. Buskin, A. Collier, 2015, Antiviral therapy.

Randomized Study of Dual Versus Single Ritonavir-Enhanced Protease Inhibitors for Protease Inhibitor-Experienced Patients with HIV

J. Mellors, A. Collier, K. Klingman, 2008, HIV clinical trials.

A randomized study of serial telephone call support to increase adherence and thereby improve virologic outcome in persons initiating antiretroviral therapy.

Heather Ribaudo, Judith Feinberg, M. Chesney, 2005, The Journal of infectious diseases.

Mechanism‐based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long‐acting anti‐HIV drug combination nanoparticle formulation

A. Collier, D. Shen, J. C. Kraft, 2018, Journal of controlled release : official journal of the Controlled Release Society.

Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine.

D. Katzenstein, P. Sax, E. Daar, 2014, Clinical Infectious Diseases.

Heavy Cannabis Use Associated With Reduction in Activated and Inflammatory Immune Cell Frequencies in Antiretroviral Therapy–Treated Human Immunodeficiency Virus–Infected Individuals

A. Collier, Michael C. Wu, N. Klatt, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Genetic Basis of Hypersusceptibility to Protease Inhibitors and Low Replicative Capacity of Human Immunodeficiency Virus Type 1 Strains in Primary Infection

J. Corbeil, J. Margolick, D. Richman, 2004, Journal of Virology.

Cerebrospinal Fluid Ceruloplasmin, Haptoglobin, and Vascular Endothelial Growth Factor Are Associated with Neurocognitive Impairment in Adults with HIV Infection

I. Grant, R. Heaton, J. Connor, 2018, Molecular Neurobiology.

Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people

F. Vaida, I. Grant, R. Heaton, 2015, Neurology.

Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort

Michael J. Taylor, D. Clifford, R. Ellis, 2011, AIDS.

Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohort

Ingrid A. Beck, J. Mullins, J. Herbeck, 2018, PLoS medicine.

The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies

B. Walker, R. Schooley, S. Little, 2018, The Journal of infectious diseases.

Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients

F. Vaida, I. Grant, R. Heaton, 2016, Journal of NeuroVirology.

HIV dynamics in seminal plasma during primary HIV infection.

A. Collier, R. Coombs, S. Holte, 2008, AIDS research and human retroviruses.

No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT.

J. Lok, R. Bosch, A. Collier, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Mitochondrial DNA Haplogroups and Neurocognitive Impairment During HIV Infection.

I. Grant, D. Murdock, R. Heaton, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Quality of Life Outcomes of Saquinavir, Zalcitabine and Combination Saquinavir plus Zalcitabine Therapy for Adults with Advanced HIV Infection with CD4 Counts between 50 and 300 Cells/mm3

R. Haubrich, A. Wu, D. Revicki, 1999, Antiviral therapy.

Phase 1 study of combination therapy with L-697,661 and zidovudine

R. Schooley, J. Phair, J. Kahn, 1996 .

What's new in treatment?

A. Collier, 1993, Journal of clinical apheresis.

Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy

I. Grant, D. Clifford, R. Ellis, 2008, Annals of neurology.

Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging Study

David A Mankoff, Janet F Eary, Jashvant D Unadkat, 2015, Drug Metabolism and Disposition.

Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders

F. Vaida, C. Fennema-Notestine, A. Gamst, 2013, Journal of NeuroVirology.

Safety and Immunogenicity of Therapeutic DNA Vaccination in Individuals Treated with Antiretroviral Therapy during Acute/Early HIV-1 Infection

E. Rosenberg, S. Little, D. Kuritzkes, 2010, PLoS ONE.

Quality of life improvement in resource-limited settings after one year of second-line antiretroviral therapy use among adult men and women

M. Hughes, U. Lalloo, A. Collier, 2018, AIDS.

Relationship of Medication Management Test-Revised (MMT-R) Performance to Neuropsychological Functioning and Antiretroviral Adherence in Adults with HIV

I. Grant, R. Heaton, D. Clifford, 2012, AIDS and Behavior.

No Evidence for an Association between Statin Use and Lower Biomarkers of HIV Persistence or Immune Activation/Inflammation During Effective ART

J. Mellors, R. Bosch, C. Rinaldo, 2019, Journal of acquired immune deficiency syndromes.

Prevalence and risk factors for HIV CSF Viral Escape: Results from the CHARTER and HNRP cohorts

I. Grant, R. Heaton, D. Clifford, 2012 .

Binge drinking is associated with differences in weekday and weekend adherence in HIV-infected individuals.

R. Gross, A. Collier, R. D. De Boni, 2016, Drug and alcohol dependence.

Interference of recombinant soluble CD4 immunoglobulin G in flow cytometric measurement of CD4+ lymphocytes.

A. Collier, L. Corey, R. Coombs, 1992, American journal of clinical pathology.

Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment : a PET Imaging Study

D. Mankoff, J. Eary, K. Domino, 2015 .

Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era.

Zhongming Zhao, P. Jia, I. Grant, 2016, The Journal of infectious diseases.

Brain morphometric correlates of metabolic variables in HIV: the CHARTER study

C. Fennema-Notestine, T. Jernigan, I. Grant, 2014, Journal of NeuroVirology.

Therapeutic Amprenavir Concentrations in Cerebrospinal Fluid

I. Grant, D. Clifford, R. Ellis, 2012, Antimicrobial Agents and Chemotherapy.

Evaluating the accuracy of self-report for the diagnosis of HIV-associated neurocognitive disorder (HAND): defining “symptomatic” versus “asymptomatic” HAND

F. Vaida, C. Fennema-Notestine, I. Grant, 2016, Journal of NeuroVirology.

Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study).

Mark Holodniy, Robert W Shafer, Daniel R Kuritzkes, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Correlates of change in cytomegalovirus viremia in patients with advanced human immunodeficiency virus infection who require transfusion.

L. Kalish, A. Collier, M. Para, 2001, The Journal of infectious diseases.

Hydroxyurea does not enhance the anti-HIV activity of low-dose tenofovir disoproxil fumarate.

A. Collier, S. Deeks, I. McGowan, 2001, Journal of acquired immune deficiency syndromes.

Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat

D. Richman, I. Grant, R. Heaton, 2012, Journal of NeuroVirology.

Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy

C. Marra, A. Collier, J. Zunt, 2003, Neurology.

F. Vaida, I. Grant, J. Keltner, 2012, Psychosomatics.

Total Raltegravir Concentrations in Cerebrospinal Fluid Exceed the 50-Percent Inhibitory Concentration for Wild-Type HIV-1

F. Vaida, I. Grant, D. Clifford, 2010, Antimicrobial Agents and Chemotherapy.

Acquired immunodeficiency syndrome. Cerebrospinal fluid findings in patients before and during long-term oral zidovudine therapy.

A. Collier, L. Corey, T. Tartaglione, 1991, Archives of neurology.

Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study

R. Parker, K. Freedberg, D. Rabideau, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance

Susanne May, Christopher H Woelk, J. Margolick, 2008, AIDS.

The impact of age on the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapy

J. Lok, R. Bosch, M. Witt, 2013, AIDS.

Comparison of clinical features, CD4 and CD8 responses among patients with acute HIV-1 infection from Geneva, Seattle and Sydney

P. Vanhems, L. Perrin, B. Hirschel, 2000, AIDS.

Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS (Journal of Infectious Diseases (2001) 183, (1466-1475))

A. Collier, M. Berrey, T. Shacker, 2008 .

Diverse HIV-1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line ART in Resource Limited Settings.

M. Hughes, R. Gross, J. Mellors, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Qualitative and Quantitative PCR Measures of Cytomegalovirus in Patients With Advanced HIV Infection Who Require Transfusions

L. Kalish, A. Collier, R. Pollard, 2001, Journal of acquired immune deficiency syndromes.

White matter damage, neuroinflammation, and neuronal integrity in HAND

C. Fennema-Notestine, I. Grant, R. Heaton, 2018, Journal of NeuroVirology.

Hodgkin's disease in homosexual men with generalized lymphadenopathy.

S. Horning, A. Collier, R. Hoppe, 1985, Annals of internal medicine.

Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202

P. Sax, E. Daar, A. Collier, 2019, Antimicrobial Agents and Chemotherapy.

Predictors of worsening neuropathy and neuropathic pain after 12 years in people with HIV

R. Heaton, D. Clifford, N. Calcutt, 2020, Annals of clinical and translational neurology.

Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team.

M. Lederman, C. Yiannoutsos, K. Marder, 1999, AIDS.

Transportability from Randomized Trials to Clinical Care: On Initial HIV Treatment with Efavirenz and Suicidal Thoughts or Behaviors.

S. Cole, D. Westreich, A. Collier, 2021, American journal of epidemiology.

Determination of indinavir, a HIV-1 protease inhibitor, in human plasma using ion-pair reversed-phase high-performance liquid chromatography.

A. Collier, R. Coombs, V. Raisys, 1999, Therapeutic drug monitoring.

Apolipoprotein E ε4 genotype status is not associated with neuroimaging outcomes in a large cohort of HIV+ individuals

F. Vaida, C. Fennema-Notestine, B. Ances, 2016, Journal of Neurovirology.

Association between U.S. State AIDS Drug Assistance Program (ADAP) Features and HIV Antiretroviral Therapy Initiation, 2001–2009

Richard D Moore, E. Stuart, Jeffrey N. Martin, 2013, PloS one.

Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection

M. Hughes, R. Shafer, G. Robbins, 2010, AIDS.

Mitochondrial DNA Haplogroups and Neurocognitive Impairment During HIV Infection.

I. Grant, R. Heaton, D. Clifford, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The impact of age on the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapy

J. Lok, R. Bosch, M. Witt, 2013, AIDS.

Low Cerebrospinal Fluid Concentrations of the Nucleotide HIV Reverse Transcriptase Inhibitor, Tenofovir

I. Grant, D. Clifford, R. Ellis, 2012, Journal of acquired immune deficiency syndromes.

The new england journal of medicine Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival

J. Goedert, B. Lau, R. Hogg, 2009 .

Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial

M. Hughes, R. Schooley, M. Weinstein, 2012, AIDS.

Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging Study

D. Mankoff, J. Eary, K. Domino, 2015, Drug Metabolism and Disposition.

Reply to Haddow et al.

F. Vaida, C. Fennema-Notestine, A. Gamst, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors

Michael J. Taylor, C. Fennema-Notestine, T. Jernigan, 2010, Journal of NeuroVirology.

Clinical factors related to brain structure in HIV: the CHARTER study

Michael J. Taylor, C. Fennema-Notestine, T. Jernigan, 2011, Journal of NeuroVirology.

HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy

Michael J. Taylor, F. Vaida, C. Fennema-Notestine, 2010, Neurology.

Total Raltegravir Concentrations in Cerebrospinal Fluid Exceed the 50-Percent Inhibitory Concentration for Wild-Type HIV-1

F. Vaida, I. Grant, D. Clifford, 2010, Antimicrobial Agents and Chemotherapy.

Effect of adjunct hydroxyurea on helper T cell immunity in HIV type 1-infected patients with virological suppression.

M. McElrath, R. Bosch, A. Collier, 2004, AIDS research and human retroviruses.

Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america.

J. Goedert, B. Lau, R. Hogg, 2011, American Journal of Epidemiology.

Clinical features of acute retroviral syndrome differ by route of infection but not by gender and age.

P. Vanhems, L. Perrin, B. Hirschel, 2002, Journal of acquired immune deficiency syndromes.

Brief Report: Differences in Difficulty Adjudicating Clinical Events in Patients With Advanced HIV Disease

L. Kalish, S. Assmann, A. Collier, 2001, Journal of acquired immune deficiency syndromes.

Primary HIV infection

A. Collier, J. Stekler, 2004, Current HIV/AIDS reports.

Early Virologic Response to Abacavir/Lamivudine and Tenofovir/Emtricitabine During ACTG A5202

D. Katzenstein, P. Sax, A. Zolopa, 2013, HIV clinical trials.

Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation.

Jeannie S. Huang, R. Haubrich, A. Zolopa, 2013, Clinical Infectious Diseases.